RecruitingNCT07027280

Noninvasive Intratumor Heterogeneity Evaluation in HNSCC

Noninvasive Intratumor Heterogeneity Evaluation in HNSCC With Multi-omics Insights and Therapeutic Targets


Sponsor

First Affiliated Hospital of Chongqing Medical University

Enrollment

700 participants

Start Date

Feb 27, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study focuses on tumor heterogeneity, a core challenge in the field of oncology, and innovatively utilizes patient imaging data to deeply mine and analyze intratumoral heterogeneity. By constructing an imaging analysis model for tumor heterogeneity and associating this model with clinical, pathological, transcriptomic, and metabolomic data of patients, a multi-omics decoding of tumor heterogeneity is achieved. The main questions it aims to address are: Can the ITH model stratify patients' treatment efficacy and prognosis assessment? Can pathological and multi-omics sequencing map the mechanisms behind the ITH model?


Eligibility

Min Age: 15 YearsMax Age: 89 Years

Inclusion Criteria1

  • Pathologically confirmed head and neck squamous cell carcinoma (HNSCC). Complete clinical, imaging, and pathological data. Available complete follow-up information.

Exclusion Criteria1

  • Patients who received chemotherapy or radiotherapy before surgery. Poor image quality. Tumors too small to be easily identified. History of other concurrent malignant tumors.

Locations(1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07027280


Related Trials